Literature DB >> 31304800

Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Outcome of Immune Checkpoint Inhibitors.

Xianhe Xie1, Junjin Liu1, Haitao Yang1, Huijuan Chen1, Sijing Zhou1, Heng Lin1, Ziyuan Liao1, Yin Ding1, Liting Ling1, Xuewen Wang1.   

Abstract

A meta-analysis of 14 studies (16 cohorts) incorporating 1751 participants was performed to evaluate the correlation between baseline neutrophil-to-lymphocyte ratio (NLR) and outcome of immune checkpoint inhibitors (ICI). The pooled hazard ratio (HR) suggested elevated pretreatment NLR was associated with poor OS (HR: 2.61, 95% confidence intervals (CI): 1.77-3.86, p < 0.00001) and PFS (HR: 1.74, 95% CI: 1.34-2.27, p < 0.0001). Stratified analyses on tumor types, ICI agents, the cutoff value of NLR and study regions exhibited the similar outcomes. This study demonstrated that elevated NLR was a predictor of poor OS and PFS for ICI.

Entities:  

Keywords:  Melanoma; immune checkpoint inhibitors (ICI); metastatic renal cell carcinoma (mRCC); neutrophil-to-lymphocyte ratio (NLR); non-small cell lung cancer (NSCLC)

Mesh：

Substances：

Year:  2019        PMID： 31304800     DOI： 10.1080/07357907.2019.1639057

Source DB:  PubMed          Journal:  Cancer Invest        ISSN： 0735-7907            Impact factor:   2.176


  10 in total

1.  Prognostic value of neutrophil-lymphocyte ratio and lactate dehydrogenase in melanoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.

Authors:  Yongchao Zhang; Bozhi Liu; Sergei Kotenko; Wei Li
Journal:  Medicine (Baltimore)       Date:  2022-08-12       Impact factor: 1.817

Review 2.  Neutrophilia, lymphopenia and myeloid dysfunction: a living review of the quantitative changes to innate and adaptive immune cells which define COVID-19 pathology.

Authors:  Amy S Codd; Stephanie J Hanna; Ewoud B Compeer; Felix C Richter; Eleanor J Pring; Ester Gea-Mallorquí; Mariana Borsa; Owen R Moon; D Oliver Scourfield; Awen M Gallimore; Anita Milicic
Journal:  Oxf Open Immunol       Date:  2021-07-15

Review 3.  Neutrophil diversity and plasticity in tumour progression and therapy.

Authors:  Sebastien Jaillon; Andrea Ponzetta; Diletta Di Mitri; Angela Santoni; Raffaella Bonecchi; Alberto Mantovani
Journal:  Nat Rev Cancer       Date:  2020-07-21       Impact factor: 60.716

4.  Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors.

Authors:  Cristina Valero; Mark Lee; Douglas Hoen; Kate Weiss; Daniel W Kelly; Prasad S Adusumilli; Paul K Paik; George Plitas; Marc Ladanyi; Michael A Postow; Charlotte E Ariyan; Alexander N Shoushtari; Vinod P Balachandran; A Ari Hakimi; Aimee M Crago; Kara C Long Roche; J Joshua Smith; Ian Ganly; Richard J Wong; Snehal G Patel; Jatin P Shah; Nancy Y Lee; Nadeem Riaz; Jingming Wang; Ahmet Zehir; Michael F Berger; Timothy A Chan; Venkatraman E Seshan; Luc G T Morris
Journal:  Nat Commun       Date:  2021-02-01       Impact factor: 14.919

5.  Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study.

Authors:  Yoon-Koo Kang; Satoshi Morita; Taroh Satoh; Min-Hee Ryu; Yee Chao; Ken Kato; Hyun Cheol Chung; Jen-Shi Chen; Kei Muro; Won Ki Kang; Kun-Huei Yeh; Takaki Yoshikawa; Sang Cheul Oh; Li-Yuan Bai; Takao Tamura; Keun-Wook Lee; Yasuo Hamamoto; Jong Gwang Kim; Keisho Chin; Do-Youn Oh; Keiko Minashi; Jae Yong Cho; Masahiro Tsuda; Hiroki Sameshima; Li-Tzong Chen; Narikazu Boku
Journal:  Gastric Cancer       Date:  2021-09-04       Impact factor: 7.370

6.  Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis.

Authors:  Edoardo Lenci; Giulia Marcantognini; Valeria Cognigni; Alessio Lupi; Silvia Rinaldi; Luca Cantini; Ilaria Fiordoliva; Anna Lisa Carloni; Marco Rocchi; Lina Zuccatosta; Stefano Gasparini; Rossana Berardi
Journal:  Explor Target Antitumor Ther       Date:  2021-06-28

7.  Prognostic value of neutrophil-to-lymphocyte ratio in advanced cancer patients receiving immunotherapy.

Authors:  D Viñal; L Gutierrez-Sainz; D Martinez; J A Garcia-Cuesta; J Pedregosa; J Villamayor; L Ostios; D Sanchez-Cabrero; O Higuera; A Pinto; N Rodriguez-Salas; E Espinosa; J de Castro; J Feliu
Journal:  Clin Transl Oncol       Date:  2020-11-23       Impact factor: 3.405

Review 8.  Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma.

Authors:  Vera Petrova; Ihor Arkhypov; Rebekka Weber; Christopher Groth; Peter Altevogt; Jochen Utikal; Viktor Umansky
Journal:  Int J Mol Sci       Date:  2020-03-30       Impact factor: 5.923

9.  Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies.

Authors:  Meghan A Cupp; Margarita Cariolou; Ioanna Tzoulaki; Dagfinn Aune; Evangelos Evangelou; Antonio J Berlanga-Taylor
Journal:  BMC Med       Date:  2020-11-20       Impact factor: 8.775

10.  The prediction potential of neutrophil-to-lymphocyte ratio for the therapeutic outcomes of programmed death receptor-1/programmed death ligand 1 inhibitors in non-small cell lung cancer patients: A meta-analysis.

Authors:  Ying Huang; Aizong Shen
Journal:  Medicine (Baltimore)       Date:  2020-08-21       Impact factor: 1.817
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.